Evaluating an Interactive Cancer Communication System (ICCS) in Lung Cancer
13 de novembro de 2019 atualizado por: University of Wisconsin, Madison
Interactive Cancer Communication System (ICCS) in Lung Cancer: Evaluating Survival Benefits. Center of Excellence in Cancer Communication Research: Using Technology to Enhance Cancer Communication and Improve Clinical Outcomes
This study will examine the potential for an Interactive Cancer Communication System (ICCS) to impact not only psychosocial outcomes such as quality of life but also length of survival in an advanced stage lung cancer population.
Two hypotheses will be tested: the Comprehensive Health Enhancement Support System- Lung Cancer (CHESS- LC) will significantly improve patient quality of life and length of overall survival as compared to a usual care control group.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
The prognosis for Non-Small Cell Lung Cancer patients remains poor despite recent advances in anti-cancer therapies.
A lung cancer diagnosis often inflicts fear, despair, and hopelessness on patients and loved ones.
For lung cancer patients in particular, a population where palliation rather than cure is often the focus, interventions addressing communication about various types of suffering are crucial to quality of life (QOL).
Our Center has done extensive research testing CHESS (Comprehensive Health Enhancement Support System), a non-commercial, web-based information and support system.
The recent Clinician Integration Project tested the impact of CHESS versus an Internet only Control group on QOL for caregivers of advanced stage lung cancer patients.
This study yielded an unanticipated finding that CHESS may have a survival benefit for patients as one year survival was significantly increased in the CHESS group (50%) compared to Internet (34.2%).
As this project did not focus on patient outcomes, follow-up with a well-formulated study designed and powered to address specific hypotheses of the nature of this effect is critical.
The proposed study will specifically test QOL and survival effects of CHESS on lung cancer patients.
Using sites in Wisconsin, Connecticut,Houston, and Chicago, we will randomly assign 376 advanced lung cancer patients to two study arms: a patient control group receiving Usual Care (including access to a computer and Internet) and a group given access to the CHESS website.
Patients may invite a caregiver to participate.
Patients will be followed for 18 months or until patient death.
Tipo de estudo
Intervencional
Inscrição (Real)
284
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Harry Gray Cancer Center at Hartford Hospital
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60612
- University of Illinois at Chicago Cancer Center
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- M.D. Anderson Cancer Center
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- All patients must be diagnosed with non-small cell lung cancer (Stage IIIA non surgical, IIIB or IV)
- All patients must be within 12 months of their primary lung cancer diagnosis or metastatic or recurrence disease.
- All patients must be at least 18 years of age,
- All patients must have an ECOG Performance Status rating of level 0, 1 or 2.
- If patients have brain metastases, they must be stable
- All patients must be under the care of a clinician who has consented to participate in the study.
- All patients must be able to speak and read English (educational attainment of at least 6th grade).
- All patients will be invited to have a caregiver also participate in the study, however this is not required.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: CHESS with Clinician Report + Internet access
An Internet-based system, Comprehensive Health Enhancement Support System for Lung Cancer(CHESS-LC) integrates over 14 services to provide tailored cancer information, support, and interactive tools.
|
The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use.
It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills.
Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services.
An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
|
|
Comparador Ativo: Usual care with Internet access
Control group patients will be given a list of URLs for 10-high quality lung cancer-related sites
|
The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use.
It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills.
Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services.
An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Compared to a Usual Care control, CHESS will significantly improve lung cancer patient Quality of Life.
Prazo: 12-month intervention
|
12-month intervention
|
|
Compared to a Usual Care control, CHESS will significantly improve patient influence length of survival of lung cancer patient.
Prazo: 12-month intervention
|
12-month intervention
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Examine the effects of CHESS use on self-determination theory (SDT) constructs.
Prazo: 12 mos.
|
12 mos.
|
|
Examine the factors that moderate effect of CHESS use on self-determination theory (SDT) constructs.
Prazo: 12 mos.
|
12 mos.
|
|
Examine whether these constructs mediate the effects of CHESS use on patient quality of life.
Prazo: 12 mos.
|
12 mos.
|
|
Examine whether treatment participation mediates the effect patient quality of life has on survival.
Prazo: 12 mos/
|
12 mos/
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Colaboradores
Investigadores
- Investigador principal: James Cleary, M.D., University of Wisconsin, Madison
- Investigador principal: Lori DuBenske, Ph.D., University of Wisconsin, Madison
Publicações e links úteis
A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.
Links úteis
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
1 de novembro de 2009
Conclusão Primária (Real)
15 de maio de 2014
Conclusão do estudo (Real)
15 de maio de 2014
Datas de inscrição no estudo
Enviado pela primeira vez
10 de novembro de 2009
Enviado pela primeira vez que atendeu aos critérios de CQ
12 de novembro de 2009
Primeira postagem (Estimativa)
13 de novembro de 2009
Atualizações de registro de estudo
Última Atualização Postada (Real)
15 de novembro de 2019
Última atualização enviada que atendeu aos critérios de controle de qualidade
13 de novembro de 2019
Última verificação
1 de março de 2019
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- M-2009-1223
- 2P50CA095817-06 (Concessão/Contrato do NIH dos EUA)
- XP08517 (Outro identificador: University of Wisconsin, Madison)
- NCI-2011-01004 (Identificador de registro: NCI Trial ID)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .